Document is current
Any future updates will be listed below
-
Authors
Sunder-Plassmann, Vincent https://orcid.org/0009-0006-9151-4139
Azizi, Amedeo A.
Farschtschi, Said
Gruber, Robert
Hutterer, Markus
Ladurner, Viktoria
Röhl, Claas
Welponer, Tobias
Bergmeister-Berghoff, Anna-Sophie
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 18 March 2024
Accepted: 27 August 2024
First Online: 12 September 2024
Conflict of interest
: A.A. Azizi is member of advisory boards for Alexion and Novartis and has received lecture honoraria from Astra Zeneca and Alexion as well as scientific grant and travel support by Alexion. A.-S. Bergmeister-Berghoff has research support from Daiichi Sankyo, Roche and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion as well as travel support from Roche, Amgen and AbbVie. S. Farschtschi has received speaker honoraria from Astra Zeneca and Alexion and compensation for advice or lecturing from Alexion not related to this study and is honorary chair of the German lay organization Bundesverband Neurofibromatose. R. Gruber received medical fees for lectures and advisory boards from Lilly, Sanofi and Pfizer. M. Hutterer has received honoraria for lectures, consultation or advisory board participation from Bristol-Meyers Squibb, Takeda, Eli Lilly and Grünenthal. C. Röhl is a member of advisory boards for Alexion and Boehringer Ingelheim and has received travel support and honoraria. V. Sunder-Plassmann, V. Ladurner and T. Welponer declare that they have no competing interests.
